[Strontium Ranelate as a new therapeutic agent for osteoporosis].
Strontium ranelate is a new chemical entity, which was recently demonstrated to reduce the fracture risk in osteoporosis patients. This unique compound has both stimulatory effect of osteoblast-mediated bone formation and inhibitory effect of osteoclast-mediated bone resorption, leading to increased bone mass.
Imanishi
Yasuo
Y
Department of Metabolism, Endocrinilogy and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Nishizawa
Yoshiki
Y
D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D010012:Osteogenesis / Q000187:drug effects; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate